跳至主要内容
临床试验/NCT02240784
NCT02240784已完成不适用

A Natural History Study of Acute Hepatic Porphyria (AHP) Patients With Recurrent Attacks

Alnylam Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 136 人开始时间: 2014年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
136
试验地点
1
主要终点
Medical history of AHP patients (Part A only)

研究概览

简要总结

The purpose of this study is to characterize the natural history and clinical management of Acute Hepatic Porphyria (AHP) patients with recurring attacks.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
12 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males and females aged >/= 12 years
  • Diagnosis of AHP [acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HCP) and aminolevulinic acid dehydratase (ALAD) deficient porphyria (ADP)]
  • Porphyria attacks in the past 12 months or receiving treatment to prevent attacks
  • Willing to provide written informed consent, medical records, and to comply with study requirements

排除标准

  • Current participation in a clinical trial of an investigational product

结局指标

主要结局

Medical history of AHP patients (Part A only)

时间窗: Baseline to 6-Month Follow-Up Visit

Medication usage of AHP patients (Part A only)

时间窗: Baseline to 6-Month Follow-Up Visit

次要结局

  • Porphyria signs and symptoms (Part A only)(0, 2, 4, 6 months)
  • Healthcare Utilization (Part A only)(0, 6 months)
  • Plasma biomarkers (Part A only)(0, 6 months and During Attacks)
  • Change in disease activity as measured by Quality of Life (Part B only)(0, 6, 12, 18, 24, 30, 36 months)
  • Change in disease activity as measured by European Organization for Research and Treatment of Cancer (EORTC) Questionnaire (Part B only)(0, 6, 12, 18, 24, 30, 36 months)
  • Quality of Life (Part A only)(0, 6 months)
  • Change in disease activity as measured by Brief Pain Inventory form (Part B only)(0, 3, 6, 9, 12, 18, 24, 30, 36 months)
  • Urine biomarkers (Part A only)(0, 6 months and During Attacks)
  • Change in disease activity as measured by Porphyria Screening/Follow Up Questionnaire (Part B only)(0, 3, 6, 9, 12, 18, 24, 30, 36 months)

研究者

发起方
Alnylam Pharmaceuticals
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验